The role of resistin and myeloperoxidase in severe sepsis and septic shock: Results from the ALBIOS trial.
Aldo BonaventuraFederico CarboneAlessandra VecchièJennifer MeessenSandra FerrarisEduardo BeckRoberto KeimSilvia MinettiEdoardo EliaDaniele FerraraAnna Maria AnsaldoDeborah NovelliPietro CaironiRoberto LatiniFabrizio MontecuccoPublished in: European journal of clinical investigation (2020)
High levels of MPO, but not of resistin, on day 1 were able to predict 90-day mortality. These findings may either suggest that early hyper-activation of neutrophils is detrimental in patients with sepsis or reflect the burden of the inflammatory process caused by sepsis. Further studies are warranted to deepen these aspects (ALBIOS ClinicalTrials.gov Identifier: NCT00707122).